Skip to main content
Premium Trial:

Request an Annual Quote

Because $999 May Not Keep Investors Happy

David Hamilton has an article at VentureBeat about how viable the business model behind companies like 23andMe will turn out to be. He predicts that these consumer genomics companies will actually get most of their revenue from pharma, which he says are likely to pay for "access to the aggregate genetic information 23andMe amasses from its customers." GTO wonders how many of these customers understand the real details of whatever privacy policy they're given.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.